
CEP37440
CAS No. 1391712-60-9
CEP37440( CEP37440 | CEP 37440 | CEP-37440 )
Catalog No. M17273 CAS No. 1391712-60-9
CEP-37440 is an effective and specific Dual FAK/ALK inhibitor with IC50s of 120 nM(ALK cellular in 75% human plasma) and 2.3 nM (FAK).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 40 | In Stock |
![]() ![]() |
5MG | 65 | In Stock |
![]() ![]() |
10MG | 115 | In Stock |
![]() ![]() |
25MG | 242 | In Stock |
![]() ![]() |
50MG | 462 | In Stock |
![]() ![]() |
100MG | 671 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameCEP37440
-
NoteResearch use only, not for human use.
-
Brief DescriptionCEP-37440 is an effective and specific Dual FAK/ALK inhibitor with IC50s of 120 nM(ALK cellular in 75% human plasma) and 2.3 nM (FAK).
-
DescriptionCEP-37440 is an orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon administration, ALK-FAK inhibitor CEP-37440 selectively binds to and inhibits ALK kinase and FAK kinase. The inhibition leads to disruption of ALK- and FAK-mediated signal transduction pathways and eventually inhibits tumor cell growth in ALK- and FAK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; its dysregulation and gene rearrangements are associated with a variety of tumors.
-
In VitroCell Viability Assay Cell Line:FC-IBC02, KPL4, SUM190, MDA-IBC03 and SUM149 cells Concentration:0, 300, 1000, 2000 and 3000 nM Incubation Time:0, 24, 48, 72, 96, 120, 144, 168, and 192 hours Result:Reduced the proliferation of three out of five IBC cell lines at low concentration. Inhibited the proliferation almost completely at 3000 nM concentration.Western Blot Analysis Cell Line:FC-IBC02, SUM 190, and KPL4 cells Concentration:1000 nM Incubation Time:0, 48, 72, 96 and 120 hours Result:Decreased phospho-FAK1 by half in FC-IBC02, SUM190, and KPL4 cells after 48 hours.
-
In Vivo——
-
SynonymsCEP37440 | CEP 37440 | CEP-37440
-
PathwayMicrobiology/Virology
-
TargetHCV
-
RecptorALK| FAK
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1391712-60-9
-
Formula Weight580.12
-
Molecular FormulaC30H38ClN7O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 41 mg/mL. 70.68 mM
-
SMILESCNC(=O)c1ccccc1Nc1nc(ncc1Cl)Nc1c(c2c(C[C@H](CCC2)N2CCN(CC2)CCO)cc1)OC
-
Chemical Name(S)-2-((5-chloro-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-1-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)amino)pyrimidin-4-yl)amino)-N-methylbenzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Iragavarapu C, et al. J Hematol Oncol. 2015 Feb 27;8(1):17.
molnova catalog



related products
-
Velpatasvir
Velpatasvir (GS-5816) is a second generation, pan-genotypic inhibitor of HCV NS5A, demonstrates a high barrier to resistance in HCV replicon assays.
-
Uprifosbuvir
A novel uridine nucleotide analog HCV NS5B polymerase inhibitor for treatment of HCV infection combined with Grazoprevir and Ruzasvir.
-
Sofosbuvir impurity ...
Sofosbuvir impurity F is both a diastereomer of Sofosbuvir and an impurity of Sofosbuvir which is an inhibitor of HCV RNA replication.